Giving Thanks Before Thanksgiving - Simcere Donates 5 million Yuan to Jiangsu Charity Federation

Trilaciclib RWS data featured at 2022 CSCO Annual Meeting: synergistic innovation enabled Chinese lung cancer patients to have preemptive access to international new drugs

Simcere and Idorsia enter into a licensing agreement for daridorexant in China

Simcere Doses First Patient in US Phase 1 Oncology Trial of its First-in-class TNFR2 Inhibitor, SIM0235

Simcere Receives IND Approval in the US for Bi-functional Fusion Protein, SIM0237 ——the Second US IND Approval This Year

Envafolimab Recommended by Two New CSCO Guidelines for Gynecological Tumors

Simcere out-licensing deal caught widespread attention from media outside China

Simcere filed 2 INDs for immune-oncology bispecific antibodies to NMPA

Enrollment completes in Global Multi-Center Phase 3 Clinical Trial of Trilaciclib in Patients with Metastatic Triple Negative Breast Cancer (TNBC)

Simcere and Almirall Enter into a Licensing Agreement for IL-2 mu Fc